What does diclofenac Epolamine do?
What does diclofenac Epolamine do?
Diclofenac epolamine patch (Flector) is a nonsteroidal anti-inflammatory drug (NSAID). It blocks the inflammation process in your body, which relieves pain and swelling.
How do you use diclofenac patch?
Apply the topical system directly to the area of pain. The patch can be worn for up to 12 hours and then removed. Apply a new patch at that time if pain continues. Do not apply diclofenac topical system on an open skin wound, or on areas of eczema, infection, skin rash, or burn injury.
Is Flector patch a controlled substance?
Flector® Patch is not a controlled substance. Diclofenac, the active ingredient in Flector® Patch, is an NSAID that does not lead to physical or psychological dependence.
What do you need to know about the Flector Patch?
DESCRIPTION. FLECTOR PATCH is a 10 cm x 14 cm patch comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
How much Diclofenac is in the Flector Patch?
FLECTOR is a 10 cm x 14 cm topical system that contains 1.3% diclofenac epolamine, and is debossed with “FLECTOR (DICLOFENAC EPOLAMINE) TOPICAL SYSTEM 1.3%.” FLECTOR (diclofenac epolamine) topical system is supplied in resealable envelopes, each containing 5 topical systems (10 cm x 14 cm), with 6 envelopes per box ( NDC 60793-411-30).
How many envelopes are in a Flector Patch?
FLECTOR (diclofenac epolamine) topical system is supplied in resealable envelopes, each containing 5 topical systems (10 cm x 14 cm), with 6 envelopes per box ( NDC 60793-411-30). Each FLECTOR is debossed with “FLECTOR (DICLOFENAC EPOLAMINE) TOPICAL SYSTEM 1.3%”.
How big is the topical system of Flector?
Flector is a 10 cm × 14 cm topical system that contains 1.3% diclofenac epolamine, and is debossed with “Flector (DICLOFENAC EPOLAMINE) TOPICAL SYSTEM 1.3%.” Flector is contraindicated in the following patients: